Former Roche Diagnostics NAM CEO Michael Tillmann joins X-ZELL executive board
Michael Tillmann as member of the company’s executive board.Singapore, August 2022 – X-ZELL is proud to announce the appointment of
Drawing on more than 30 years of experience in the pharmaceutical and diagnostics industry, Mr Tillmann previously held the CEO position at Roche Diagnostics North America and Asia Pacific. Between 2006 and 2010, he also served as a member of the company’s global executive board.
Since then, Mr Tillmann has been actively investing in, advising and incubating companies under the Amatargroup umbrella, with recent transactions including the sale of Singaporean diagnostics start-up Vela Diagnostics to Luye Lifescience and German mRNA company AmpTec GmbH to Merck Millipore.
Mr Tillmann will join X-ZELL Founder & CEO Dr Sebastian Bhakdi, COO Johannes Hille and Siam Commercial Bank (SCB) Chairman, Dr Vichit Suraphongchai, on the X-ZELL board. He also invested an undisclosed sum into the company.
“After already working with the founding team for three years, I feel excited and privileged to finally take on this role at such an invigorating and inspiring company,” Mr Tillmann commented.
“X-ZELL’s single-cell technology could genuinely change the way we think about cancer diagnostics as it will make powerful new data available from non-invasive sources – in a format that is scalable and fit for the digital age.”
X-ZELL Founder & CEO, Dr Sebastian Bhakdi, said: “Michael’s long history of leadership and experience in the start-up space make him a perfect fit for X-ZELL as we prepare for the next growth stage. I look forward to working closely with him to continue our journey to make non-invasive, affordable cancer diagnostics accessible to everyone.”
Managing Director X-ZELL Biotech Pte. Ltd.
X-ZELL is an award-winning medical technology company specialising in the detection and digitization of atypical cells from body liquids such as blood and pleural fluid. Atypical cells are the universal language of cancer diagnostics and commonly found in tissue or fluid samples that were surgically collected from the suspected site. By enabling cytology centres worldwide to detect atypical cells in non-invasive sample material and process them digitally at a new level of detail, we make highly accurate, non-invasive diagnostics accessible at scale.
© 2023 X-ZELL INC